Tim Kanter

Tim Kanter is the CCO of Prescient Medicine, a company focused on producing tools that target patient outcomes and management in two key areas – medication interaction and medication efficacy –including the validated genetic test designed to predict individual risk of opioid addiction, LifeKit® Predict. Tim has worked for major pharmaceutical and biopharmaceutical companies including Baxalta/Baxter, Novo Nordisk, and ALTANA Pharma in both US and global roles. Most recently, he consulted with a variety of companies in the preparation and launch of new products and initiatives within multiple therapeutic areas. Tim holds a BS from the University of Florida and an MBA from the University of South Florida.

Tim Kanter is the Vice President Market Access, Trade and Pricing at Orphazyme, based in United States, North America. With a background in Biotechnology, Tim Kanter has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.